Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Naproxcinod
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Nicox SA
Deal Size : Inapplicable
Deal Type : Inapplicable
Nicox Updates on Fera Pharmaceuticals’ Continuing Evaluation of Naproxcinod
Details : Naproxcinod, a Cyclooxygenase-Inhibiting Nitric Oxide (NO)-Donating (CINOD) naproxen, is a non-steroidal anti-inflammatory product candidate engineered to release NO and naproxen, originally discovered and developed by Nicox.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 30, 2021
Lead Product(s) : Naproxcinod
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Nicox SA
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naproxcinod
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Nicox SA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Naproxcinod is a nonsteroidal anti-inflammatory product candidate engineered to release NO and naproxen, originally discovered and developed by Nicox. Fera will evaluate naproxcinod as a potential adjuvant treatment for patients with COVID-19 infection.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 12, 2020
Lead Product(s) : Naproxcinod
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Nicox SA
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydrocortisone
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Recipient : Koffler Vision Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
May 23, 2013
Lead Product(s) : Hydrocortisone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Recipient : Koffler Vision Group
Deal Size : Inapplicable
Deal Type : Inapplicable